Accessibility Menu
Alzex Neuropharma logo

Alzex Neuropharma(OTC) TRRI

Market Cap$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-99%
1 Year-99%
1 Month-67%
$0.00
+0.00%
+0.00Today
Alzex Neuropharma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-14
Alzex Neuropharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-66.67%USD 0.002026-07-02
1 month-66.67%USD 0.002026-06-08
3 month-20%USD 0.002026-04-14
Year to date+100%USD 0.002025-12-30
1 year-99.44%USD 0.072025-05-16
3 year-99.92%USD 0.502023-06-29
5 year-99%USD 0.042021-07-15
Since inception-100%USD 30,000.302008-07-14

Alzex Neuropharma Financials at a Glance

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$254.12K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

4.92 (High)

Price

$0.00

Volume

334

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.07

Estimated Earnings Date

N/A

TRRI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alzex Neuropharma

Trinity Resources Inc. is a mineral exploration and mining development company focused on gold, silver, and platinum group metals across North and South America. The firm is known for its Eureka Placer Claim in California and has undergone a rebranding from TruLan Resources Inc. since September 2015.

Products and Services
  • Mineral exploration in precious metals
  • Mining development projects in North and South America
  • Focus on gold, silver, and platinum group metals
Growth Outlook
  • Potential for increased demand in precious metals due to economic conditions
  • Strategic positioning in regions with rich mineral deposits
  • Ongoing exploration efforts may lead to new discoveries
Financial Highlights
  • Recent quarterly net income of -$85,579
  • Trailing twelve months (TTM) revenue remains at $0
  • Current liabilities significantly exceed current assets
Trinity Resources Inc. operates in a sector that is sensitive to market fluctuations and economic conditions, particularly in the precious metals industry. The company's focus on exploration and development positions it to potentially benefit from rising demand for these metals. However, recent financial data indicates challenges, including a net income loss and a lack of revenue generation. The current liabilities significantly surpass current assets, highlighting the need for careful financial management. Investors may find the company's strategic positioning and ongoing exploration efforts noteworthy, as they could lead to future growth opportunities in a recovering market.
AI Generated • Jul 14, 2026

Industry

Metals and Mining

Sector

Materials

CEO

Robert W. Rosner

Website

trinresinc.com

Headquarters

Las Vegas, NV 89052, US

TRRI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

122.39%

Return on Capital

N/A

Return on Assets

-844.65%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.51M

Volume

334

Avg. Volume

12.238

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$246.85K

EBITDA

-$246.85K

Operating Cash Flow

-$37.94K

Capital Expenditure

$0.00

Free Cash Flow

-$37.94K

Cash & ST Invst.

$160.00

Total Debt

$117.12K

Alzex Neuropharma Performance Analysis

Alzex Neuropharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
Alzex Neuropharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Q22024-06-30N/A
Alzex Neuropharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 0.01N/A
20222022-12-31USD -0.11N/A
Alzex Neuropharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31-89.9%
Q22023-06-3047.0%
Q32023-09-30N/A
Q22024-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$600.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$54.55

N/A

Employees

11

N/A

Net Income

-$85.58K

-99.0%

EBITDA

-$83.68K

-804.3%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$160.00

-84.3%

Total Debt

$117.12K

+28.4%

Accounts Receivable

$6.46K

-51.2%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$117.12K

+28.4%

Return on Assets

-8.45%

N/A

Return on Invested Capital

74.97%

N/A

Free Cash Flow

-$3.59K

+94.0%

Operating Cash Flow

-$3.59K

+94.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BKSLFBanks Island Gold Ltd.
$0.00+0.00%
RKTEReflectkote, Inc.
$0.00+0.00%
CNTOCentor Energy, Inc.
$0.00+0.00%
GPLDFGreat Panther Mining Ltd
$0.00-90.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About TRRI

What is the current price of Alzex Neuropharma?

Alzex Neuropharma is trading at $0.00 per share.

What is the 52-week range for Alzex Neuropharma?

Over the past 52 weeks, Alzex Neuropharma has traded between $0.00 and $0.07.

How much debt does Alzex Neuropharma have?

As of the most recent reporting period, Alzex Neuropharma reported total debt of $91.20K.

How much cash does Alzex Neuropharma have on hand?

Alzex Neuropharma reported $1.02K in cash and cash equivalents in its most recent financial results.

What is Alzex Neuropharma’s dividend yield?

Alzex Neuropharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services